Faina Gutin, MD
Allergy & Immunology · Sewell, NJNPI 1578666707
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (37.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by CSL Behring at 41.7% of the total. Reporting peaked in 2019 at $4,411 and has fallen 85.2% since, to $653 in 2025.
Across 195 payments — averaging $47.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$4K
- Biocryst Pharmaceuticals, Inc.$2K
- AstraZeneca$1K
- Optinose US, Inc.$834
- GSK$538
- Pharming Healthcare, Inc.$217
- plus $1K from 18 others
What the payments were for
- Consulting fees$2,55027%
- Speaking & faculty fees$3,30035%
- Food & beverage$3,46637%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 32 | $3,896 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,750 |
| AstraZeneca | 39 | $1,092 |
| Optinose US, Inc. | 4 | $834 |
| GSK | 36 | $538 |
| Pharming Healthcare, Inc. | 14 | $217 |
| Sanofi | 16 | $204 |
| Novartis | 8 | $125 |
| Amgen | 5 | $86 |
| Regeneron Healthcare Solutions, Inc. | 6 | $85 |
| Kaleo, Inc. | 6 | $85 |
| Genentech USA, Inc. | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Biocryst US Sales Co., LLC | 4 | $59 |
| Pfizer | 3 | $39 |
| Grifols USA, LLC | 2 | $33 |
| Greer Laboratories, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $25 |
| Bio Products Laboratory USA, Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Alk-abello, Inc | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,340 in reported general payments places this provider in the 70th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 12 | $494,157 |
| GlassiaAlpha-1-Proteinase Inhibitor | 12 | $129,245 |
| ZyfloZileuton | 11 | $36,867 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,745 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $12,639 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $6,502 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $4,258 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $4,212 |
| Epinephrine | 18 | $3,316 |
| Azelastine Hcl | 78 | $2,770 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,370 |
| Qvar RedihalerBeclomethasone Dipropionate | 11 | $2,365 |
| Desloratadine | 23 | $2,127 |
| Fluticasone Propionate | 130 | $1,815 |
| Mometasone Furoate | 19 | $1,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $59 | $494,15712 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $69 | $129,24512 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $538 | $28,38341 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $2,36511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Sewell
- Ellen SherOcean$1M
- Peter RickettiTrenton$457K
- John KimMedford$339K
- Tina ZeccaLittle Silver$262K
- George BelecanechVoorhees$208K
- Jacqueline RossOcean$131K
- Shirin JadidiMendham$98K
- Mark WeinsteinBelleville$88K
- Joseph GrizzantiHawthorne$79K
- Lisa BariscianoFlorham Park$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.